The lowest pCR rate was observed in HR-positive Her2 negative breast cancers (complete pCR: 0%, breast pCR: 6.25%, nodal pCR: 18.75%), compared to Her2 positive (complete pCR: 64.29%, breast pCR: 64.29%, nodal pCR: 78.57%) and triple-negative tumors (complete pCR: 40%, breast pCR: 50%, nodal pCR: 60%). This evidence concerns the gene ERBB2 and breast carcinoma.